APOBEC3G and HIV-1: Strike and counterstrike

Current Infectious Disease Reports

Volumn 8, Issue 4, 2006, Pages 317-323

  Soros, Vanessa B ^b   Greene, Warner C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; DEAMINASE; DEOXYCYTIDINE; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS DNA;

CELL PROTECTION; DRUG DESIGN; DRUG TARGETING; HELPER CELL; HOST; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR WEIGHT; NONHUMAN; RETROVIRUS; REVERSE TRANSCRIPTION; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; VIRUS MUTATION;

EID: 33746072598     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0077-6     Document Type: Review

References (54)

1. Gabuzda DH, Lawrence K, Langhoff E, et al.: Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 1992, 66:6489-6495.
2. Sova P, Volsky DJ: Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol 1993, 67:6322-6326.
3. von Schwedler U, Song J, Aiken C, Trono D: Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993, 67:4945-4955.
4. Madani N, Kabat D: An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol 1998, 72:10251-10255.
5. Simon JH, Gaddis NC, Fouchier RA, Malim MH: Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 1998, 4:1397-1400.
6. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
7. Jarmuz A, Chester A, Bayliss J, et al.: An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79:285-296.
8. Harris RS, Petersen-Mahrt SK, Neuberger MS: RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 2002, 10:1247-1253.
9. Cullen BR: Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 2006, 80:1067-1076.
10. Mangeat B, Trono D: Lentiviral vectors and antiretroviral intrinsic immunity. Hum Gene Ther 2005, 16:913-920.
11. Chiu YL, Greene WC: The APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. J Biol Chem 2006, 281:8309-8312.
12. Yu Q, Konig R, Pillai S, et al.: Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 2004, 11:435-442.
13. Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR: Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol 2005, 79:10978-10987.
14. Berkhout B, van Hemert FJ: The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins. Nucleic Acids Res 1994, 22:1705-1711.
15. Bronson EC, Anderson JN: Nucleotide composition as a driving force in the evolution of retroviruses. J Mol Evol 1994, 38:506-532.
16. Fitzgibbon JE, Mazar S, Dubin DT. A new type of G → A hypermutation affecting human immunodeficiency virus. AIDS Res Hum Retroviruses 1993, 9:833-838.
17. Borman AM, Quillent C, Charneau P, et al.: A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G→A hypermutation during negative-strand viral DNA synthesis. Virology 1995, 208:601-609.
18. Janini M, Rogers M, Birx DR, McCutchan FE: Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol 2001, 75:7973-7986.
19. Koulinska IN, Chaplin B, Mwakagile D, et al.: Hypermutation of HIV type 1 genomes isolated from infants soon after vertical infection. AIDS Res Hum Retroviruses 2003, 19:1115-1123.
20. Vartanian JP, Henry M, Wain-Hobson S: Sustained G→A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. J Gen Virol 2002, 83:801-805.
21. Stopak K, de Noronha C, Yonemoto W, Greene WC: HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003, 12:591-601.
22. Kao S, Miyagi E, Khan MA, et al.: Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 2004, 1:27.
23. Mehle A, Goncalves J, Santa-Marta M, et al.: Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cu15 complex that promotes APOBEC3G degradation. Genes Dev 2004, 18:2861-2866.
24. Chiu YL, Soros VB, Kreisberg JF, et al.: Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005, 435:108-114.
25. Kreisberg JF, Yonemoto W, Greene WC: Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med 2006, 203:865-870.
26. Newman EN, Holmes RK, Craig HM, et al.: Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 2005, 15:166-170.
27. Xu H, Svarovskaia ES, Barr R, et al.: A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A 2004, 101:5652-5657.
28. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR: A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 2004, 23:2451-2458.
29. Ribeiro AC, Maia e Silva A, Santa-Marta M, et al.: Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol 2005, 79:823-833.
30. Mahieux R, Suspene R, Delebecque F, et al.: Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J Gen Virol 2005, 86:2489-2494.
31. Navarro F, Bollman B, Chen H, et al.: Complementary function of the two catalytic domains of APOBEC3G. Virology 2005, 333:374-386.
32. Sasada A, Takaori-Kondo A, Shirakawa K, et al.: APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2005, 2:32.
33. Gunther S, Sommer G, Plikat U, et al.: Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G→A hypermutation. Virology 1997, 235:104-108.
34. Suspene R, Guetard D, Henry M, et al.: Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A 2005, 102:8321-8326.
35. Noguchi C, Ishino H, Tsuge M, et al.: G to A hypermutation of hepatitis B virus. Hepatology 2005, 41:626-633.
36. Rosler C, Kock J, Kann M, et al.: APOBEC-mediated interference with hepadnavirus production. Hepatology 2005, 42:301-309.
37. Rosler C, Kock J, Malim MH, et al.: Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science 2004, 305:1403. Author reply 1403.
38. Turelli P, Mangeat B, Jost S, et al.: Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004, 303:1829.
39. Tanaka Y, Marusawa H, Seno H, et al.: Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem Biophys Res Commun 2006, 341:314-319.
40. Deininger PL, Batzer MA: Mammalian retroelements. Genome Res 2002, 12:1455-1465.
41. Turelli P, Vianin S, Trono D: The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J Biol Chem 2004, 279:43371-43373.
42. Esnault C, Heidmann O, Delebecque F, et al.: APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 2005, 433:430-433.
43. Bogerd HP, Wiegand HL, Doehle BP, et al.: APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 2006, 34:89-95.
44. Schumacher AJ, Nissley DV, Harris RS: APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci U S A 2005, 102:9854-9859.
45. Dutko JA, Schafer A, Kenny AE, et al.: Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr Biol 2005, 15:661-666.
46. Sawyer SL, Emerman M, Malik HS: Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2004, 2:E275.
47. Zhang J, Webb DM: Rapid evolution of primate antiviral enzyme APOBEC3G. Hum Mol Genet 2004, 13:1785-1791.
48. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS: Evolution of the AID/APOBEC family of polynucleotide (deoxy) cytidine deaminases. Mol Biol Evol 2005, 22:367-377.
49. An P, Bleiber G, Duggal P, et al.: APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004, 78:11070-11076.
50. Do H, Vasilescu A, Diop G, et al.: Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J Infect Dis 2005, 191:159-163.
51. Jin X, Brooks A, Chen H, et al.: APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficie1ncy virus viremia. J Virol 2005, 79:11513-11516.
52. Cho SJ, Drechsler H, Burke RC, et al.: APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. J Virol 2006, 80:2069-2072.
53. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR: A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A 2004, 101:3770-3774.
54. Schrofelbauer B, Chen D, Landau NR: A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A 2004, 101:3927-3932.